Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 4/20 | 0.48 |
| ▸ | FEN1 | P39748 | 4/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 6/20 | 0.43 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 4/20 | 0.41 |
| ▸ | BACE1 | P56817 | 2/20 | 0.41 |
| ▸ | CTSD | P07339 | 1/20 | 0.41 |
| ▸ | APLNR | P35414 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30190300 | 0.86 | EPHA2 (0.52) | — | |
| SCHEMBL23084832 | 0.86 | EPHA2 (0.52) | — | |
| SCHEMBL31298902 | 0.86 | CHEK2 (0.49) | ALOX5APFEN1SCN9ACHEK2HTR6 | |
| SCHEMBL24936313 | 0.85 | ALOX5AP (0.45) | ALOX5APFEN1SCN9ACHEK2 | |
| SCHEMBL30190413 | 0.84 | ALOX5AP (0.48) | ALOX5APFEN1SCN9ACHEK2HTR6 | |
| SCHEMBL30190430 | 0.84 | ALOX5AP (0.45) | ALOX5APFEN1SCN9ACHEK2HTR6 | |
| SCHEMBL24936158 | 0.82 | CHEK1 (0.41) | ALOX5APFEN1SCN9A | |
| SCHEMBL30190446 | 0.82 | CHEK1 (0.57) | CHEK2 | |
| SCHEMBL31298918 | 0.81 | ALOX5AP (0.47) | ALOX5APFEN1SCN9ACHEK2 | |
| SCHEMBL27157955 | 0.80 | SCN9A (0.55) | ALOX5APFEN1SCN9ACHEK2HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12492197-B2 | 3,5-disubstituted pyrazole compounds as kinase inhibitors and uses thereof | Impact Therapeutics (Shanghai), Inc (CN) | 2025-12-09 | — | — | US | disclosed |
| US-20220356181-A1 | 3,5-DISUBSTITUTED PYRAZOLE COMPOUNDS AS KINASE INHIBITORS AND USES THEREOF | Impact Therapeutics (Shanghai), Inc (CN) | 2022-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220356181-A1 | 3,5-DISUBSTITUTED PYRAZOLE COMPOUNDS AS KINASE INHIBITORS AND USES THEREOF | CHEK1, CHEK2, CDK2 | ALOX5AP 4301/4885FEN1 225/4885SCN9A 4379/4885 |
| US-12492197-B2 | 3,5-disubstituted pyrazole compounds as kinase inhibitors and uses thereof | CHEK1, CHEK2, CCNK | ALOX5AP 4600/4885FEN1 310/4885SCN9A 3982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.